News
Stay Ahead with the Latest Industry Trends & Market Insights with Industry News 📰

Nasopharyngeal Cancer Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: July 2024 || SKU: PH3102
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Get Free Sample

See how US Tariffs impact Nasopharyngeal Cancer Market

Don’t get caug

Nasopharyngeal Cancer Market is segmented By Therapy (Chemotherapy, Immunotherapy, Radiation therapy, Others), By End User (Hospitals & Clinics, Ambulatory surgery centers Electronics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

 

Nasopharyngeal Cancer Market Overview

(170pages) A Report by DataM Intelligence estimates the Global Nasopharyngeal Cancer market to grow at a  CAGR Of 4.7% during the forecast period 2024-2031. The market is expected to grow due to increasing demand from Hospitals & Clinics, Ambulatory surgery centers Electronics. The competitive rivalry intensifies with Bristol-Myers Squibb Co, Merck & Co., Inc.., Novartis International AG, and others operating in the market.

Nasopharyngeal cancer is a rare therapy of malignant cancer that appears in the nasopharynx. It is the upper part of the throat behind the nose. The nasopharynx is situated at the base of the skull, directly above the roof of the mouth. Nasopharyngeal cancer generally starts in the squamous cells that track the nasopharynx. The exact sources of nasopharyngeal cancer are unknown; however, a few risk factors are linked with nasopharyngeal cancer. Exposure to the Epstein-Barr virus is deemed a common risk factor for nasopharyngeal cancer. Also, people of East Asian or Chinese ancestry are more prone to cancer. Early symptoms of nasopharyngeal cancer involve a sore throat, lump in the nose or neck, difficulty in breathing or speaking, difficulty in hearing, pain or ringing in the ear or headaches. The nasopharyngeal cancer market has grown significantly at a strong CAGR due to the increasing patient count with nasopharyngeal cancer. The nasopharyngeal cancer market will likely grow globally with technological advancement and innovation.

 

Nasopharyngeal Cancer Market Scope

Metrics

Details

Market CAGR

4.7%

Segments Covered

By Therapy, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

 

To know more insights Download Sample

 

Nasopharyngeal Cancer Market Dynamics

Increasing awareness regarding nasopharyngeal cancer drive market growth

There is a rising awareness of the diagnosis and treatment of nasopharyngeal cancer. Conventionally, the public perception concerning nasopharyngeal cancer was low due to the lack of government initiatives and the relatively low incidence rate of the disease. To boost community awareness for ethnicities prone to nasopharyngeal cancer, several primary healthcare centers have begun awareness campaigns to enhance the awareness of nasopharyngeal cancer. Therefore, greater adoption of nasopharyngeal cancer diagnosis and treatment is being witnessed, driving the growth of the global nasopharyngeal cancer market.

However, the High treatment cost of nasopharyngeal cancer negatively impacted the market growth. The high price of therapeutic procedures, such as chemotherapy, surgeries, and radiation therapy, results in out-of-pocket expenditure among non-insured cancer patients. The high price of drugs adds to the overarching financial burden of the treatment. It can act as a barrier to the global nasopharyngeal cancer treatment market. With so many advantages of the nasopharyngeal cancer market, it has a few disadvantages too. The high cost of the treatment and side effects are a barrier to the nasopharyngeal cancer market.

Nasopharyngeal Cancer Market Segmentation Analysis

The cryosurgery devices segment will project the fastest growth in the market throughout the forecast period

Based on therapy, the nasopharyngeal cancer market has been classified into chemotherapy, immunotherapy, radiation therapy and others

Radiation Therapy is expected to hold a significant market share in the treatment therapy segment. Radiation therapy forms the main modality of treatment for nasopharyngeal cancer. Newer and advanced solutions for nasopharyngeal cancer treatment include a combination of both chemotherapy and radiotherapy techniques. These treatment modalities are at an early clinical phase and will make a commercial appearance late during the end of the forecast period.

Based on the End User, the animal stem cell therapy market has been classified into hospitals & clinics, ambulatory surgery centers and others

The hospitals & clinics segment is anticipated to hold the largest share in the global market. The rapid adoption of technologies is expected to boost the nasopharyngeal cancer treatment market. This trend is likely seen in emerging regions where healthcare expenditure is increasing considerably. Developed regions are observing that since the availability of nasopharyngeal cancer treatment and procedure is easily available, the demand for the nasopharyngeal cancer market has increased. Companies are investing heavily in emerging regions to offer efficient treatment solutions for higher healthcare quality, greater efficiency and better patient outcomes.

Nasopharyngeal Cancer Market Geographical Share

Asia Pacific is the dominating region during the forecast period.

Based on geography, the study analyzes the animal stem cell therapy market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

The Asia Pacific is expected to witness the fastest growth during the forecast period. In the Asia Pacific, nasopharyngeal cancer is one of the most widespread cancers in the head and neck areas. Men are two to three times more likely to grow it than women. The peak age of prevalence is between 50 and 60 years. This cancer is generally more common in Southeast Asia. Moreover, the five countries with the greatest incidence of nasopharyngeal cancer worldwide were Indonesia, China, Vietnam, India and Malaysia, respectively. According to the research published by the American Cancer Society, in some parts of China, there are as many as 25 to 30 cases per 100,000 men and 15 to 20 cases per 100,000 women. Developed regions are witnessing that since accessibility for nasopharyngeal cancer treatment and procedures are easily accessible and available, the demand for the nasopharyngeal cancer market has increased. Companies are investing heavily in developing regions to offer effective treatment solutions for higher care quality, greater efficiency and better patient outcomes. Moreover, increasing healthcare awareness, along with increasing spending on IT and healthcare technologies in developing regions, is expected to boost the overall demand for effective treatment in the nasopharyngeal cancer market.

Nasopharyngeal Cancer Market Companies and Competitive Landscape

The nasopharyngeal cancer market is highly competitive, owing to the presence of big competitive players in the market. Some major key players in the market are  Bristol-Myers Squibb, Cyclacel Pharmaceuticals Inc., Eli Lilly And Co., GLAXOSMITHKLINE PLC, Merck & Co., Inc., Novartis International AG, ONO PHARMACEUTICAL CO. Safoni, Theravectys SA, among others. The major players are adopting new product launches and expansion strategies for global growth in the nasopharyngeal cancer market. In March 2022, Bristal Mayer Squibb acquired Turning Point Therapeutics, a Leading Precision Oncology Company, for $76.00 per Share. This acquisition helps to expand companies leading oncology franchise by adding a best-in-class, late-stage precision oncology asset. In July 2021, Eli Lilly announced the acquisition of promoter technologies, a private biotech company, to advance treatment for type 1 diabetes (TD1) for $1bn. This acquisition accelerates next-generation life-changing therapies for people living with T1D. In April 2021, GLAXOSMITHKLINE PLC, a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, acquired Sierra Oncology; a California based Biopharmaceutical Company focused on targeted therapies for the treatment of rare disease Cancer, for USD 1.9 Billion. This acquisition includes momelotinib, a late-stage potential new medicine with a unique dual mechanism of action that may address the critical unmet medical needs of myelofibrosis patients with anemia. This acquisition helps to expand the innovative oncology portfolio.

COVID-19 Impact on Nasopharyngeal Cancer

Negative impact on the global nasopharyngeal cancer market.

The COVID-19 pandemic has hampered the growth of the nasopharyngeal cancer market, owing to the decline in hospital visits and the diagnosis rate of the disease amidst the pandemic. Cancer patients are predominantly elderly and immunosuppressed, and clinical data shows that they may be more susceptible to Covid 19 infection. The major concern during the COVID-19 pandemic was to stay safe at home and boost immunity, which has declined clinic visits, leading to the downfall in the nasopharyngeal cancer market in 2020.

The global nasopharyngeal cancer market report would provide an access to approximately 50 market data tables, 42 figures and 170 pages.

Buy this report
Single User
$4350$3480
Multiple User
$4850$3880
Enterprise User
$7850$6280
Proceed to Buy
  Get Free Sample
  Request new version
  Customize Sample
  Demo Full Report
Chat on WhatsApp
FAQ’s

  • Nasopharyngeal Cancer Market is expected to grow at a CAGR Of 4.7% during the forecast period 2024-2031

  • Key players are Bristol-Myers Squibb, Cyclacel Pharmaceuticals Inc., Eli Lilly And Co., GLAXOSMITHKLINE PLC, Merck & Co., Inc., Novartis International AG, ONO PHARMACEUTICAL CO. Safoni, and Theravectys SA.
Related Reports
pharmaceuticals iconpharmaceuticals

Europe Liver Cancer Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 March 05

Starting from

$3750

pharmaceuticals iconpharmaceuticals

Salivary Gland Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2023 October 04

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Urinary Tract Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2023 October 06

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Triple Negative Breast Cancer Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 October 22

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Silent Cancer Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 August 01

Starting from

$4350

pharmaceuticals iconpharmaceuticals

US Prostate Cancer Instruments and Test Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 November 29

Starting from

$3175

WhatsApp